CN113384595A - Application of miR-674-3p in preparation of medicine for preventing or treating stress hypertension - Google Patents
Application of miR-674-3p in preparation of medicine for preventing or treating stress hypertension Download PDFInfo
- Publication number
- CN113384595A CN113384595A CN202110789623.1A CN202110789623A CN113384595A CN 113384595 A CN113384595 A CN 113384595A CN 202110789623 A CN202110789623 A CN 202110789623A CN 113384595 A CN113384595 A CN 113384595A
- Authority
- CN
- China
- Prior art keywords
- mir
- stress
- hypertension
- pressure
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of miR-674-3p in preparation of a medicine for preventing or treating stress hypertension, and discloses that inhibition of miR-674-3p expression can effectively reduce heart rate, renal sympathetic nerve activity, mean arterial pressure, systolic pressure and diastolic pressure of a stress hypertension rat. miR-674-3p can be used as a new molecular target for treating stress hypertension and guides the screening and research and development of related medicaments.
Description
(I) technical field
The invention relates to application of miR-674-3p in preparation of a medicine for preventing or treating stress hypertension.
(II) background of the invention
With the rapid development of social economy, the rhythm of life is accelerated continuously, the working pressure is increased day by day, and various intense competitions lead the spirit of people to be continuously tensed and the stress to be intensified, so that the hypertension is generated, and the hypertension is called as stress hypertension. Stress hypertension is an important risk factor for diseases such as cerebral apoplexy and coronary heart disease, the incidence rate of the stress hypertension is gradually increased year by year, the stress hypertension is in a youthful trend, and the stress hypertension is extremely harmful. The medulla oblongata head-end ventral lateral region is one of the key central nuclei for cardiovascular activity regulation and plays an important role in regulation and control in stress hypertension. Stress causes a series of gene expression and regulation changes in the abdominal lateral region of the medulla oblongata head end, which causes sympathetic nerve excitation and increases blood pressure. Therefore, the research on endogenous molecules involved in the gene expression regulation of the extraabdominal region of the medulla oblongata head end has great practical significance, and the endogenous molecules are important targets for treating the stress hypertension.
miRNA is a highly conserved endogenous non-coding small RNA molecule with length of about 17 to 25 nucleotides, is widely distributed in eukaryotes, mainly regulates and controls the expression of genes at the level of posttranscription, and plays an important role in the processes of cell differentiation, ontogeny and disease occurrence and development. At present, the research on the relation between miRNA regulation and stress hypertension is very limited, and the action of medulla oblongata head end abdominal lateral region miR-674-3p in the aspect of regulating the stress hypertension is not reported.
Disclosure of the invention
The invention aims to provide application of miR-674-3p in preparation of a medicine for preventing or treating stress hypertension, and the application has great significance in clinical prevention or treatment of stress hypertension.
The technical scheme adopted by the invention is as follows:
the invention provides application of miR-674-3p in preparation of a medicine for preventing or treating stress hypertension.
The miR-674-3p is miRNA, and the nucleotide sequence is shown in SEQ ID NO. 1.
The nucleotide sequence of miR-674-3p is as follows: 5'-CACAGCUCCCAUCUCAGAAC-3' are provided.
The drug is one of the following: the medicine for reducing the heart rate of the stress hypertension, the medicine for reducing the renal sympathetic nerve activity of the stress hypertension and the medicine for reducing the mean arterial pressure, the systolic pressure or the diastolic pressure of the stress hypertension.
The application is to inhibit the expression of miR-674-3p, and the inhibitor (namely miR-674-3p antagomir) for inhibiting the expression of miR-674-3p is single-stranded RNA with the nucleotide sequence of 5'-GUUCUGAGAUGGGAGCUG UG-3' (SEQ ID NO. 8).
The method for regulating and controlling the stress hypertension by using miR-674-3p comprises the following steps:
firstly, establishing a stress hypertension rat model.
Secondly, miRNA-seq sequencing is carried out on the medullary cephalic and abdominal lateral region tissues of the stress hypertensive rat and the normal control rat which respectively have 3 biological repeats, miRNAs with P <0.05 are screened according to the P value in the differential expression analysis result, and the result shows that miR-674-3P shows obvious high expression in the medullary cephalic and abdominal lateral region of the stress hypertensive rat.
Thirdly, qPCR quantitative primers of miR-674-3p and internal reference U6 are designed, expression conditions of miR-674-3p in the medulla oblongata head-end abdominal lateral region of stress hypertensive rats and normal control rats are further detected through qPCR, and results show that the miR-674-3p is remarkably high-expressed in the medulla oblongata head-end abdominal lateral region of the stress hypertensive rats and are consistent with miRNA-seq results.
Fourthly, a miR-674-3p inhibitor (namely miR-674-3p antagomir) and a negative control (namely NC antagomir) are synthesized and are injected bilaterally in the medullary head end abdominal region of a stress hypertensive rat, and the result shows that the inhibition of the expression of miR-674-3p can remarkably reduce the heart rate, renal sympathetic nerve activity, mean arterial pressure, systolic pressure and diastolic pressure of the stress hypertensive rat.
The miR-674-3p qPCR quantitative primer comprises a miR-674-3p upstream primer, a miR-674-3p downstream primer and a miR-674-3p reverse transcription primer, and the sequences are respectively shown as SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO. 4.
The quantitative primers of the internal reference U6 qPCR comprise an upstream primer of the internal reference U6, a downstream primer of the internal reference U6 and a reverse transcription primer of the internal reference U6, and the sequences of the primers are respectively shown as SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO. 7.
The miR-674-3p antagomir is single-stranded RNA, and the sequence is shown in SEQ ID NO. 8.
The NC antagomir is single-stranded RNA, and the sequence is shown as SEQ ID NO. 9.
Compared with the prior art, the invention has the following beneficial effects:
the invention discloses that the inhibition of miR-674-3p expression can effectively reduce the heart rate, renal sympathetic nerve activity, mean arterial pressure, systolic pressure and diastolic pressure of a stress hypertensive rat. miR-674-3p can be used as a new molecular target for treating stress hypertension and guides the screening and research and development of related medicaments.
(IV) description of the drawings
Fig. 1, comparison of heart rate (a), renal sympathetic activity (B), mean arterial pressure (C), systolic pressure (D) and diastolic pressure (E) in rats in the stress group and the control group 15 days after modeling with intermittent plantar shock combined with continuous noise stress. And (3) SIH: stress hypertensive rats; control: normal control rats; heart rate: heart rate; renal systematic negative activity: renal sympathetic nerve activity; mean iterative compression: mean arterial pressure; systolic blood pressure: contracting pressure; a Diastolic blood pressure: and (4) relaxing the pressure.
FIG. 2, HeatMap clustering analysis of 4 significantly differentially expressed miRNAs revealed by miRNA-seq. And (3) SIH: stress hypertensive rats; control: normal control rats.
FIG. 3, results of qPCR validation of miR-674-3 p. And (3) SIH: stress hypertensive rats; control: normal control rats.
FIG. 4 shows the inhibitory effect of miR-674-3p antagomir on the expression of miR-674-3p in the extraabdominal region of the medulla oblongata head of a stress hypertensive rat. And (3) SIH: stress hypertensive rats.
FIG. 5 is a graph showing the change in heart rate after the expression of miR-674-3p is inhibited in the extraabdominal region of the medulla oblongata of a stress hypertensive rat. And (3) SIH: stress hypertensive rats; heart rate: heart rate.
FIG. 6, change in renal sympathetic nerve activity after inhibition of miR-674-3p expression in the extraabdominal region of the medullary head of a stress hypertensive rat. And (3) SIH: stress hypertensive rats; renal systematic negative activity: renal sympathetic nerve activity.
FIG. 7 shows changes in mean arterial pressure (A), systolic pressure (B) and diastolic pressure (C) after inhibition of miR-674-3p expression in the ventral lateral region of the medullary head of a stressed hypertensive rat. And (3) SIH: stress hypertensive rats; mean iterative compression: mean arterial pressure; systolic blood pressure: contracting pressure; a Diastolic blood pressure: and (4) relaxing the pressure.
(V) detailed description of the preferred embodiments
The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto:
by combining with specific examples, the application of miR-674-3p in the aspect of regulating stress hypertension is further detailed, so that the purpose and the technical scheme of the invention can be more clearly understood. It should be noted that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. Unless otherwise specified, the experimental procedures used in the examples are all conventional in the art. Unless otherwise specified, the reagent consumables used in the examples are commercially available.
Example 1 establishment of stress hypertensive rat model
The animal Experimental center provided healthy adult male SD (Sprague-Dawley) rats of 7 weeks of age, 50, weighing 230- & 260 g. The animals were kept in SPF-class animal houses with free water diet, room temperature was maintained at 23 + -1 deg.C, relative humidity 50%, and standard day-night 12 h cycle. Rats were randomly divided into two groups, a stress hypertension group and a normal control group, each group consisting of 25 rats, and molding was started after adaptive feeding for 3 days.
Rats in the stressed hypertensive rat group were placed in a molded cage (22cm × 22cm × 28cm) and subjected to intermittent shock stimulation (voltage 50V, duration 50ms each, interval 2s) on their soles with continuous noise stimulation (buzzer production, 90 dB). The whole process is controlled by a computer program, and the stress is applied once every morning and afternoon, 2 hours for each time and lasts for 15 days. Rats in the normal control rat group were also placed in the molding cage at the same time each day, but did not receive a foot shock and noise stimulation. Heart rate, renal sympathetic activity, mean arterial pressure, systolic pressure and diastolic pressure measurements were taken 15 days after stress stimulation.
The femoral catheterization method measures heart rate and blood pressure. Rats were anesthetized with sodium pentobarbital (50mg/kg) by intraperitoneal injection, mounted on a console, and the console temperature was maintained at 37 ℃. The hair at the groin on the right side is removed by the scissors, the skin is cut off after disinfection, and the femoral artery is separated. The proximal end of the femoral artery is clamped by an artery clamp, and the distal end of the femoral artery is ligated to block the blood flow to form a closed lumen. The vessel wall was cut with scissors from a 0.3cm position above the distal femoral ligation line and the vessel was properly dilated with forceps. The arterial cannula (filled with 200IU/mL heparinized saline) is inserted obliquely from the opening to the depth of about 2.0 cm. The arteries were cannulated and then connected to ｃA pressure transducer and the heart rate, mean arterial pressure, systolic pressure and diastolic pressure of the rats were recorded by ｃA SMUP-A type bio-signal acquisition processing system (Shanghai medical university).
Renal sympathetic nerve activity was recorded. After the heart rate and blood pressure measurements were completed in the rats described above, the hair on the back was removed with scissors, the skin on the back of the rats was cut after sterilization, the subcutaneous fascia tissue was further cut, the left renal vessels and the abdominal aorta were found and they were exposed to the visual field with the aid of a spreader. The exposed renal arteries and abdominal aorta were observed with a magnifying glass, and renal sympathetic nerves were found and isolated. Then slowly hanging the renal sympathetic nerves on a clean bipolar silver wire recording electrode, wrapping the renal sympathetic nerves and the electrode by Wacker Silgel 932 Wacker silica gel, and recording the activity of the renal sympathetic nerves by a PowerLab/8SP (AD instruments) biological signal acquisition and processing system. The value recorded after the steady discharge of renal sympathetic nerves is taken as the basal renal sympathetic nerve activity value (generally occurring around 25-30 min). Rats were then euthanized by intravenous overdose with pentobarbital sodium and maximal renal sympathetic activity values (typically around 5min after overdose with pentobarbital sodium) were recorded. Noise renal sympathetic nerve activity values (typically occurring around 20-30min after overdose with sodium pentobarbital) were recorded after the renal sympathetic nerves had completely ceased discharging. And finally, calculating by a formula: (basal renal sympathetic nerve activity value-noisy renal sympathetic nerve activity value)/(maximum renal sympathetic nerve activity value-noisy renal sympathetic nerve activity value).
After 15 days of intermittent plantar shock combined with continuous noise stress modeling, the results of comparing heart rate, renal sympathetic nerve activity, mean arterial pressure, systolic pressure and diastolic pressure of the stressed hypertensive rat group and the normal control rat group are shown in fig. 1. Compared with the normal control rat group, the heart rate, renal sympathetic nerve activity, mean arterial pressure, systolic pressure and diastolic pressure of the stress hypertensive rat group are all obviously increased (P <0.01 and P <0.001), and the modeling is successful.
Example 2miRNA-seq revealed that miR-674-3p is significantly highly expressed in the extraabdominal region of medulla oblongata head of stress hypertensive rat
Stress hypertensive rats and normal control rats were randomly selected 3 each, and total RNA was extracted from the ventral outer region of the medulla oblongata of 6 rats by Trizol (Invitrogen) method. Utilizing agarose gel electrophoresis, Nanodrop ND-2000 ultramicro spectrophotometer (Thermo),
The Fluorometer (Invitrogen) and Agilent 2100 bioanalyzer (Agilent) assessed the quality of total RNA. Three distinct 28S, 18S and 5S bands are required to be visible after agarose gel electrophoresis, the 28S brightness is twice that of 18S, and the 5S is darkest; OD260/OD280 value is between 1.8-2.0; the RNA integrity value (RIN) is greater than 8.0.
Constructing a miRNA-Seq library by using a Tru Seq Small RNA Sample Prep Kits (Illumina) kit, wherein the construction comprises the steps of connecting 3 'and 5' linkers, performing reverse transcription amplification, performing gel purification on the amplified cDNA library, and performing quality inspection on the cDNA library. The quality-qualified cDNA library was sequenced using Illumina HiSeq 2500 with a single-ended 1X 50bp read length.
After sequencing to obtain raw data (raw reads), the following analyses were performed using the ACGT101-miR software: (1) removing the joint and the garbage sequence to obtain clean reads; (2) preserving reads with the base length of 18-26 bp; (3) comparing the residual reads to databases such as RFam and Redbase, and further filtering; (4) comparing the filtered reads to miRNA precursors and genomes for miRNA identification; (5) and (4) analyzing miRNA differential expression. 4 significantly differentially expressed miRNAs were identified by miRNA differential expression analysis with P-values less than 0.05(P <0.05), and HeatMap cluster analysis is shown in fig. 2. Wherein miR-674-3p shows obvious high expression in the abdominal lateral region of medulla oblongata head of a stress hypertensive rat.
The nucleotide sequence of miR-674-3p is as follows:
miR-674-3p：5’-CACAGCUCCCAUCUCAGAAC-3’(SEQ ID NO.1)。
example 3 qPCR validation of miR-674-3p expression
Total RNA was extracted from the medullary-cephalad ventral region of stressed hypertensive rats and normal control rats using Trizol (Invitrogen). By using
II 1st Strand cDNA Synthesis Kit (Yeasen) Kit for reverse transcription Synthesis of cDNA. The 20ul qPCR system included: 7.2. mu.L of ultrapure water, 10. mu.L
qPCR SYBR Green Master Mix (Yeasen), 0.4. mu.L of the forward primer, 0.4. mu.L of the reverse primer, and 2. mu.L of cDNA. The reaction apparatus was a Bio-Rad CFX96 touch qPCR system (Bio-Rad). The reaction procedure was as follows: the first step is 95 ℃ for 5 min. The second step is 40 cycles comprising 95 ℃ for 10 s; 60 ℃ for 20 s; 72 ℃ for 20 s. U6 was used as an internal reference gene. The results are shown in figure 3, and the expression of miR-674-3P in the extraabdominal region of medulla oblongata of the stress hypertensive rat is obviously higher than that of the normal control rat (. about.P)<0.05), consistent with miRNA-seq results.
The primers used for detecting miR-674-3p are as follows:
miR-674-3p upstream primer: 5'-CGCGCACAGCTCCCATCT-3' (SEQ ID NO. 2);
miR-674-3p downstream primer: 5'-AGTGCAGGGTCCGAGGTATT-3' (SEQ ID NO. 3);
miR-674-3p reverse transcription primer:
5’-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGTTCTG-3’(SEQ ID NO.4)。
primers used to detect U6 were as follows:
u6 upstream primer: 5'-GCTTCGGCAGCACATATACTAAAAT-3' (SEQ ID NO. 5);
u6 downstream primer: 5'-CGCTTCACGAATTTGCGTGTCAT-3' (SEQ ID NO. 6);
u6 reverse transcription primer: 5'-CGCTTCACGAATTTGCGTGTCAT-3' (SEQ ID NO. 7).
Example 4 inhibition of miR-674-3p expression in the medullary cephalic and ventral lateral region of stress hypertensive rat significantly reduces rat heart rate, renal sympathetic nerve activity, mean arterial pressure, systolic pressure and diastolic pressure
Rats of the 15-day-stressed hypertensive rat group of example 1 were anesthetized with sodium pentobarbital (50mg/kg) by intraperitoneal injection and randomly divided into 3 groups (model group, miR-674-3p antagomir, NC antagomir). The model group was stress hypertensive rats without any treatment; the miR-674-3p antagomir and NC antagomir components are respectively prepared by injecting artificially synthesized miR-674-3p inhibitor (miR-674-3p antagomir with the concentration of 1 nmol/mu L and DEPC water) and negative control (NC antagomir with the concentration of 1 nmol/mu L and DEPC water) at the two sides of the abdominal lateral area of the medulla oblongata head through a brain stereotaxic apparatus, and 2 mu L of the miR-674-3p antagomir and the NC antagomir are respectively injected at each side. After 48 hours of injection, the inhibitory effect was measured by qPCR, and the expression level of miR-674-3P in the miR-674-3P antagomir group was significantly decreased (P <0.01) compared to the model group and the NC antagomir group, and the result is shown in fig. 4, and the qPCR method was the same as in example 3. After the stressed hypertensive rat medullary cephalic lateral region inhibits the expression of miR-674-3P, the heart rate (see figure 5), renal sympathetic nerve activity (see figure 6), mean arterial pressure (see figure 7), systolic pressure (see figure 7) and diastolic pressure (see figure 7) are all significantly reduced (P <0.01 and P <0.001), and the detection method is the same as that of example 1.
The miR-674-3p antagomir is a single-chain structure and has the following sequence:
miR-674-3p antagomir：5’-GUUCUGAGAUGGGAGCUGUG-3’(SEQ ID NO.8)。
NC antagomir is a single-chain structure, and the sequence of the NC antagomir is as follows:
NC antagomir：5’-CAGUACUUUUGUGUAGUACAA-3’(SEQ ID NO.9)。
while the preferred embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the invention.
Sequence listing
<110> Zhejiang university of traditional Chinese medicine
Application of miR-674-3p in preparation of medicine for preventing or treating stress hypertension
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> RNA
<213> Artificial Synthesis (Unknown)
<400> 1
<210> 2
<211> 18
<212> DNA
<213> Artificial Synthesis (Unknown)
<400> 2
cgcgcacagc tcccatct 18
<210> 3
<211> 20
<212> DNA
<213> Artificial Synthesis (Unknown)
<400> 3
<210> 4
<211> 50
<212> DNA
<213> Artificial Synthesis (Unknown)
<400> 4
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgttctg 50
<210> 5
<211> 25
<212> DNA
<213> Artificial Synthesis (Unknown)
<400> 5
gcttcggcag cacatatact aaaat 25
<210> 6
<211> 23
<212> DNA
<213> Artificial Synthesis (Unknown)
<400> 6
cgcttcacga atttgcgtgt cat 23
<210> 7
<211> 23
<212> DNA
<213> Artificial Synthesis (Unknown)
<400> 7
cgcttcacga atttgcgtgt cat 23
<210> 8
<211> 20
<212> RNA
<213> Artificial Synthesis (Unknown)
<400> 8
<210> 9
<211> 21
<212> RNA
<213> Artificial Synthesis (Unknown)
<400> 9
caguacuuuu guguaguaca a 21
Claims (7)
1. Application of miR-674-3p in preparation of medicines for preventing or treating stress hypertension.
2. The use according to claim 1, characterized in that the miR-674-3p nucleotide sequence is: 5'-CACAGCUCCCAUCUCAGAAC-3' are provided.
3. Use according to claim 1, characterized in that the medicament is a medicament for reducing the heart rate of stress-induced hypertension.
4. The use of claim 1, wherein said medicament is a medicament for reducing renal sympathetic nerve activity associated with stress-induced hypertension.
5. Use according to claim 1, characterized in that the medicament is a medicament for reducing the mean arterial, systolic or diastolic blood pressure of stress-induced hypertension.
6. The use according to claim 1, characterized in that said use is the inhibition of the expression of miR-674-3 p.
7. Use according to claim 1, characterized in that the inhibitor of miR-674-3p for inhibiting the expression of miR-674-3p is a single-stranded RNA having the nucleotide sequence 5'-GUUCUGAGAUGGGAGCUGUG-3'.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110789623.1A CN113384595B (en) | 2021-07-13 | 2021-07-13 | Application of miR-674-3p in preparation of medicine for preventing or treating stress hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110789623.1A CN113384595B (en) | 2021-07-13 | 2021-07-13 | Application of miR-674-3p in preparation of medicine for preventing or treating stress hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113384595A true CN113384595A (en) | 2021-09-14 |
| CN113384595B CN113384595B (en) | 2022-08-02 |
Family
ID=77625890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110789623.1A Active CN113384595B (en) | 2021-07-13 | 2021-07-13 | Application of miR-674-3p in preparation of medicine for preventing or treating stress hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113384595B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023092927A1 (en) * | 2021-09-08 | 2023-06-01 | 中国人民解放军空军军医大学 | Small rna for relieving stress hypertension vascular endothelial dysfunction and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103210089A (en) * | 2010-08-13 | 2013-07-17 | 格拉斯哥大学大学行政评议会 | Therapeutic uses of microvesicles and related microRNAs |
| CN103667459A (en) * | 2013-11-26 | 2014-03-26 | 上海中医药大学附属岳阳中西医结合医院 | Application of microRNA to hypertension diagnose and antihypertension medication preparation |
| CN104357555A (en) * | 2013-11-26 | 2015-02-18 | 上海中医药大学附属岳阳中西医结合医院 | Application of microRNA (ribonucleic acid) has-miR574-3p in hypertension diagnosis |
| US20190264212A1 (en) * | 2016-07-20 | 2019-08-29 | Thomas Jefferson University | Inhibiting microrna to prevent development of essential hypertension |
| CN110846319A (en) * | 2019-12-05 | 2020-02-28 | 广西国际壮医医院 | Human intron-derived 27-base microRNA and application thereof in blood pressure regulation |
| CN111494400A (en) * | 2020-05-11 | 2020-08-07 | 福建中医药大学 | Function of miRNA-483-3p in regulating blood pressure, heart and blood vessels of spontaneous hypertensive rat |
| WO2021016425A1 (en) * | 2019-07-24 | 2021-01-28 | St. Jude Children's Research Hospital, Inc. | Mirnas for reducing ventricle enlargement |
-
2021
- 2021-07-13 CN CN202110789623.1A patent/CN113384595B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103210089A (en) * | 2010-08-13 | 2013-07-17 | 格拉斯哥大学大学行政评议会 | Therapeutic uses of microvesicles and related microRNAs |
| CN103667459A (en) * | 2013-11-26 | 2014-03-26 | 上海中医药大学附属岳阳中西医结合医院 | Application of microRNA to hypertension diagnose and antihypertension medication preparation |
| CN104357555A (en) * | 2013-11-26 | 2015-02-18 | 上海中医药大学附属岳阳中西医结合医院 | Application of microRNA (ribonucleic acid) has-miR574-3p in hypertension diagnosis |
| US20190264212A1 (en) * | 2016-07-20 | 2019-08-29 | Thomas Jefferson University | Inhibiting microrna to prevent development of essential hypertension |
| WO2021016425A1 (en) * | 2019-07-24 | 2021-01-28 | St. Jude Children's Research Hospital, Inc. | Mirnas for reducing ventricle enlargement |
| CN110846319A (en) * | 2019-12-05 | 2020-02-28 | 广西国际壮医医院 | Human intron-derived 27-base microRNA and application thereof in blood pressure regulation |
| CN111494400A (en) * | 2020-05-11 | 2020-08-07 | 福建中医药大学 | Function of miRNA-483-3p in regulating blood pressure, heart and blood vessels of spontaneous hypertensive rat |
Non-Patent Citations (2)
| Title |
|---|
| 伍燕宏等: ""基于GEO数据库对原发性高血压的差异靶基因分析"", 《临床心血管病杂志》 * |
| 何诚: "《实验动物学》", 31 March 2006, 中国农业大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023092927A1 (en) * | 2021-09-08 | 2023-06-01 | 中国人民解放军空军军医大学 | Small rna for relieving stress hypertension vascular endothelial dysfunction and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113384595B (en) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102892897B (en) | The compositions of micro-RNA expression analysis of spectrum and method for pulmonary carcinoma | |
| US10435689B2 (en) | MicroRNA inhibition for the treatment of inflammation and myeloproliferative disorders | |
| Suomalainen et al. | Quantification of tRNA3243Leu point mutation of mitochondrial DNA in MELAS patients and its effects on mitochondrial transcription | |
| CN113384595B (en) | Application of miR-674-3p in preparation of medicine for preventing or treating stress hypertension | |
| CN109680039A (en) | A kind of construction method and kit in the genetic test library of heredity arotic disease | |
| CN112239782A (en) | Detection kit for clopidogrel metabolic marker | |
| CN107028970A (en) | Applications of the miR 1288 in diagnosing or treating osteoarthritis disorders | |
| CN110201172A (en) | Application of the YY1 expression inhibiting agent in preparation treatment breast cancer medicines | |
| CN112126686B (en) | Early-stage screening molecular marker for renal fibrosis and application thereof | |
| CN110684842A (en) | Application of miR144-3p as liver-lung syndrome marker | |
| CN114432332B (en) | Application of circUTRN in preparation of heart failure treatment medicine, recombinant vector and heart failure treatment medicine | |
| KR102321429B1 (en) | Composition for diagnosing aging of stem cells using USP12 expression level detection | |
| CN111394356B (en) | Endogenous long-chain non-coding RNA MRAK049966 and application thereof | |
| CN112107589B (en) | Application of miRNA-328a-3p in preparation of vascular injury repair or vascular growth regulation and control medicine | |
| CN115851908A (en) | Application of lncRNA-INPP5F in preparation of medicine for preventing or treating stress hypertension | |
| CN102586237A (en) | Poly-nucleic acid molecule and application thereof | |
| CN113952455B (en) | Application of MOGS inhibitor in preparation of peripheral nerve regeneration promoting medicine | |
| CN112263587B (en) | Application of miR-3065-5p in preparation of medicine for preventing and/or treating renal fibrosis | |
| CN108118093A (en) | Purposes of the LINC00426 in bone and flesh tumor metastasis diagnostic products are prepared | |
| CN112266954B (en) | Application of miR-125b-2-3p in renal fibrosis | |
| CN112094895B (en) | MiRNA for diagnosis and treatment of atopic dermatitis | |
| CN115252787B (en) | Use of Zip7 for inhibiting opioid-induced hyperalgesia | |
| CN117065023A (en) | Function and application of TTK gene and TTK inhibitor in treatment of restenosis after vascular injury | |
| CN111321145B (en) | SiRNA of schistosoma japonicum PHB1 and PHB2 genes and application thereof | |
| CN112023046B (en) | Application of miR-2115in diagnosis and treatment of atopic dermatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |